Long-Term Safety of Intravenous Ibandronic Acid for Up to 4 Years in Metastatic Breast Cancer
Background and objective: Despite their widespread use in metastatic bone disease, some bisphosphonate drugs are associated with adverse events (AEs), particularly renal toxicity, adding to treatment burdens and increasing healthcare costs. Ibandronic acid is a single-nitrogen bisphosphonate with high efficacy against bone events and metastatic bone pain, and a renal safety profile comparable to that of placebo. In this study, the safety of ibandronic acid was examined over a period of 4 years.
Patients and methods: During an initial 96-week period, breast cancer patients with bone metastases were randomised in double-blind fashion to placebo or ibandronic acid 6mg administered by intravenous infusion over 1–2 hours every 3–4 weeks as part of a previously reported phase III trial (MF 4265 study). All patients completing the phase III trial were offered open-label active treatment for a further 96 weeks (extension phase). A total of 62 patients received ibandronic acid 6mg in this extension phase and were classified according to their initial treatment (placebo/ibandronic acid 6mg [placebo/6mg] and ibandronic acid 6mg/ ibandronic acid 6mg [6mg/6mg] groups). Safety was assessed by AE reports and clinical laboratory evaluations.
Results: During the 4-year study, most patients experienced at least one AE, with malignancy progression being most commonly reported. However, fewer treatment-related AEs were reported in the extension phase (placebo/6mg: 6.3% [1/16]; 6mg/6mg: 13.0% [6/46]) than in the initial phase of the study (placebo: 56.3% [9/16]; 6mg: 67.4% [31/46]). Serious AEs were mainly due to malignancy progression. There were no clinically relevant renal AEs, and in both groups, serum creatinine levels were similar for up to 4 years.
Conclusion: This 96-week open-label safety extension of a phase III, placebo-controlled trial demonstrates that long-term use of intravenous ibandronic acid is well tolerated.
The clinical trial and data analysis were conducted by Roche. The authors would like to thank Thomson Gardiner-Caldwell US for their editorial support.
Dr Pecherstorfer is a member of a Roche drug safety advisory board. The other authors have no conflicts of interest that are directly relevant to the contents of this study.
- 6.Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735–44PubMedCrossRefGoogle Scholar
- 7.Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial —The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21: 3150–7PubMedCrossRefGoogle Scholar
- 10.Johnson KB, Gable P, Kaime EM, et al. Significant deterioration in renal function with the new bisphosphonate, zoledronic acid [abstract no. 2968]. J Clin Oncol 2003; 22 Suppl.: 738Google Scholar
- 11.Kloth DD, McDermott RS, Rogatko A, et al. Impact of zoledronic acid on renal function in patients with cancer: is constant monitoring necessary [abstract no. 3036]? J Clin Oncol 2003; 22 Suppl.: 755Google Scholar
- 12.Stein SH, Davidson R, Tweed A, et al. Renal dysfunction with IV bisphosphonates in patients with metastatic breast cancer [abstract no. 2997]. J Clin Oncol 2003; 22 Suppl.: 745Google Scholar
- 14.De Cock E, Hutton K, Canney P, et al. Cost-effectiveness of oral ibandronic acid versus i.V. zoledronic acid and i.V. pamidronate in the treatment of metastatic bone disease in breast cancer [abstract no. 189P]. Ann Oncol 2004; 15Suppl. 3: iii 50Google Scholar
- 15.Bauss F, Endele R, Besenfelder E, et al. Ibandronate: serum kinetics, tissue distribution and binding to bone following intravenous bolus injection [abstract no. P-128]. Calcif Tissue Int 2002; 70: 289–90Google Scholar
- 16.Pfister T, Bauss F, Body JJ. The risk of cumulative renal effects of intravenous bisphosphonates [abstract no. 859P]. Ann Oncol 2004; 15Suppl. 3: iii 226Google Scholar
- 18.Cancer Therapy Evaluation Program. Common toxicity criteria version 2.0 [online]. DCTD, NCI, NIH, DHHS. 1999 Apr 30. Available from URL: http://ctep.cancer.gov/reporting/ctc.html [Accessed 2006 May 10]
- 19.Heidenreich A, Ohlmann C, Olbert P, et al. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer [abstract no. 897]. Eur J Cancer 2003; 1: S270Google Scholar
- 23.Hutton J, De Cock E, Barrett-Lee P, et al. Cost-effectiveness of i.v. ibandronic acid versus i.v. zoledronic acid and i.v. pamidronate for metastatic bone disease from breast cancer [abstract no. 191P]. Ann Oncol 2004; 15Suppl. 3: iii 50Google Scholar
- 25.Pecherstorfer M, Bergström B. Safety of intravenous (i.v.) and oral ibandronate for up to 4 years in patients with metastatic breast cancer [abstract no. 186P]. Ann Oncol 2004; 15Suppl. 3: iii 49Google Scholar